SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is surging on reports of a groundbreaking partnership with Novo Nordisk to sell obesity drugs, ending a prior feud. This unexpected alliance, announced late Friday, has fueled immense speculation about a massive short squeeze, leaving a highly shorted float vulnerable and sparking widespread bullish sentiment.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending after reporting strong Q4 and full-year revenue and customer asset growth, despite an EPS miss attributed to increased growth investments. Community sentiment is deeply divided, with many citing deep undervaluation and significant institutional buying, while others criticize management for sustained price declines and concerns over dilution.

SHP ETF Trust - FIS Biblically Responsible Risk Managed ETF

The $PRAY ETF is trending as widespread community discussion centers on the intersection of faith, biblical principles, and financial decision-making, directly reflecting its "Biblically Responsible" investment strategy. Users are engaging in conversations about ethical investing, seeking divine guidance in wealth management, and debating the morality of various market practices.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA) is seeing significant action after its acquisition of TikTok icon Khaby Lame's core company, sparking intense speculative interest due to its low float and high insider ownership, as traders weigh massive short squeeze potential against sharp warnings of a pump-and-dump.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines is trending as its CEO warns of a significant Q1 earnings impact from surging jet fuel prices, a direct result of Middle East geopolitical tensions. Despite strong passenger demand, the community is divided between those fearing further declines due to fuel costs and others buying the dip, anticipating a rebound.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending following robust full-year earnings that showcased record revenue, improved profitability, and a substantial AI infrastructure pipeline, sparking community discussions about its perceived undervaluation and market dynamics amidst a challenging small-cap environment.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is buzzing as the CEO's recent discussion of 'curative outcomes' for its AML therapies drives community speculation of groundbreaking REGAL trial data and a potential buyout, intensified by an ongoing AML conference and growing short squeeze chatter.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. ($ASST) is generating significant debate as a Bitcoin treasury company, with bulls seeing a deeply undervalued opportunity given its substantial BTC holdings and potential for an amplified move as Bitcoin targets new highs. However, skeptics decry its model as a "dilution machine," citing high operational costs and past reverse splits that erode shareholder value despite Bitcoin's performance.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF ($XBI) is garnering significant attention due to recent M&A activity within the sector and optimistic speculation regarding a more favorable regulatory landscape following shifts in FDA leadership. The community is actively discussing the potential for a substantial short squeeze, fueling expectations for a broader biotech rally.

AABG Token

AABBG CRYPTO is trending amidst strong community anticipation for its new AABB Wallet and the silver-backed AABBS token launch, fueled by bullish sentiment on substantial gold and silver holdings and a federal lawsuit targeting alleged market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Predictive Oncology Inc. (POAI) drew significant interest from retail investors after the company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million, which will support its adoption of a digital asset treasury strategy.The firm stated that the principal holding will be the native utility token of the Aethir ecosystem.The two private transactions are expected to close on or about October 2. The funds will be used to support the company’s digital asset treasury strategy, for the acquisition of ATH in the open market, and for working capital and general corporate purposes, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-inc-announces-private-placements-344-million">stated</a>.Last week, Predictive Oncology also <a href="https://stocktwits.com/news-articles/markets/equity/predictive-oncology-shares-tumble-on-reverse-stock-split-announcement/chDl1r4R3IR">announced</a> a 1-for-15 reverse stock split of its issued and outstanding shares of common stock, which became effective at 12:01 a.m. on Tuesday, Sept. 30, 2025. The split is designed to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange. Following the split, the company lowered its shares of common stock to 762,000 from over 11.4 million.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of Dec. 31, 2024, and a stockholders' deficit of approximately $1.7 million.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-spotify-stock-is-slipping-2-in-premarket/chDDP1nR3Bg">Why Spotify Stock Is Slipping 2% In Premarket</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Predictive Oncology Stock Receives Significant Investor Interest Today – Here Are Two Important Developments

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.

Equity

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.


Shares of Predictive Oncology Inc. (POAI) tumbled 19% on Thursday after the company announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock.The reverse stock split will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/25/3156239/37244/en/Predictive-Oncology-Announces-1-for-15-Reverse-Stock-Split.html">become</a> effective at 12:01 a.m. on Tuesday, September 30, the company said. The reverse stock split is primarily aimed at bringing the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the bourse.At the effective time of the reverse stock split, every 15 shares of Predictive Oncology’s issued and outstanding common stock will be combined automatically into one share of common stock. While the company currently has over 11.4 million shares of common stock, it will be reduced to about 762,000 after the split, the firm added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_2_16_32_PM_png_9c3fdd1117.webp" alt="POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock will fall below $0.50 before the reverse stock split becomes effective.<stembedurl>https://stocktwits.com/MillionaireTrader555/message/629988968</stembedurl>Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of December 31, 2024, and a stockholders' deficit of approximately $1.7 million.POAI stock is up 17% this year and approximately 22% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiziana-life-sciences-stock-rises-on-advancing-second-asset/chDl0MtR34z">Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Shares Tumble 19% On Reverse Stock Split Announcement – More Details Inside

The reverse stock split is primarily intended to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange.

Shares of Predictive Oncology Inc. (POAI) fell to their lowest level in a month on Thursday, drawing&nbsp;significant retail attention. Renovaro announced that its 2025 lawsuit to enforce a merger agreement with POAI will proceed on an expedited trial schedule.Renovaro, a TechBio company specializing in diagnostics and genetically enhanced cancer therapies, said the Delaware Court of Chancery approved its motion to fast-track a&nbsp;lawsuit filed earlier this month.&nbsp;Predictive Oncology shares closed down 10.1% at $0.98 on Thursday, holding steady in after-hours trading.The case stems from an alleged breach of a binding merger agreement signed on Jan. 1.According to Renovaro’s complaint, the agreement required POAI to merge into Renovaro in exchange for a new class of preferred stock.&nbsp;Renovaro claims that Predictive Oncology violated exclusivity and good faith clauses by raising $545,000 in a public offering in February and attempting to terminate the agreement unilaterally in April.The company&nbsp;now seeks specific performance, injunctive relief, and damages for the alleged breaches.In its Form 10-Q filing dated May 14, Predictive Oncology said that while the two companies entered into a binding letter of intent for the merger on Jan. 1, and extended the agreement’s termination date to March 31, no definitive purchase agreement was signed by that date.&nbsp;Predictive Oncology’s board notified Renovaro on April 3 that merger discussions were discontinued and that the company has no further obligations under the letter of intent or extension agreement.&nbsp;The company dismissed Renovaro’s lawsuit as without merit and said it intends to “vigorously” contest the case.The dispute unfolds as Predictive Oncology continues to promote its use of AI and machine learning in drug discovery, citing access to a biobank of over 150,000 live tumor samples.&nbsp;The company said its platform modeled tumor responses for 21 previously untested compounds.On Stocktwits, retail sentiment was ‘bullish’ amid a 2,200% surge in 24-hour message volume.One retail user said they held no position in POAI but were invested in Renovaro and hoped the merger would be completed.&nbsp;<stembedurl>https://stocktwits.com/Stengaard1/message/615590359</stembedurl>Another user suggested POAI could deliver unexpected gains, predicting the stock might rally suddenly.<stembedurl>https://stocktwits.com/EarlofLondon/message/615526666</stembedurl>The stock has risen 6.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish

Renovaro said the Delaware Court of Chancery had approved an expedited trial schedule for the lawsuit it filed to enforce a binding merger agreement with Predictive Oncology.

Axe Compute, Inc. engages in the application of artificial intelligence medicine and the provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment consists of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	--	-$107.25	--	N/A
Q2 '25	--	-$3.30	--	N/A
Q1 '25	--	-$0.32	--	N/A
Q4 '24	-$3.75	--	--	N/A
Q3 '24	-$0.32	-$0.48	-50.00%	MISSED

POAI
Predictive Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest POAI News

POAIPredictive Oncology Inc